Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Kohei Shitara(National Cancer Center Hospital East), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Roberto Pazo-Cid(Hospital Universitario Miguel Servet), Ahsan M. Arozullah(Astellas Pharma (United States)), David H. Ilson(Memorial Sloan Kettering Cancer Center), Florian Lordick(Leipzig University), Yung‐Jue Bang(Seoul National University), Pranob Bhattacharya(Astellas Pharma (United States)), Diarmuid Moran(Astellas Pharma (United States)), Mok Oh(Astellas Pharma (United States)), Manish A. Shah(NewYork–Presbyterian Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Jung Wook Park(Astellas Pharma (United States)), Jianming Xu(Chinese PLA General Hospital), Jianning Yang(Astellas Pharma (United States)), Yoon‐Koo Kang(Ulsan College), Rui‐Hua Xu(Sun Yat-sen University), Joseph Chao(Amgen (United States))
The Lancet
April 15, 2023
10.1016/s0140-6736(23)00620-7
Cited by 701

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gastric cancer
|The Lancet|2020|4.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k